| News

Boehringer Ingelheim acquires Basel’s NBE-Therapeutics

10.12.2020

German pharma group Boehringer Ingelheim is to acquire the Basel life sciences company NBE-Therapeutics for €1.18 billion. NBE-Therapeutics specializes in the development of cancer therapies.

NBE-Therapeutics is to become part of Boehringer Ingelheim. The Basel company is being acquired for €1.18 billion. It will remain at its campus at the Technology Park Basel and operate as a new site within Boehringer Ingelheim’s R&D network. ”This transaction is a validation of our platform and its potential for the next generation cancer therapies,” said Bertrand Damour, Chief Executive Officer of NBE-Therapeutics, in a press release.

The Basel biotech company is focused on antibody-drug conjugates (ADC) and advancing targeted cancer therapies derived from its immune stimulatory platform. The lead compound NBE-002 is currently in phase I clinical studies for triple negative breast cancer and other solid tumors.

Boehringer Ingelheim is gaining access to an innovative and unique platform that will decisively expand its cancer immunology portfolio. “We welcome NBE-Therapeutics’ richly talented team to Boehringer Ingelheim and we look forward to collaborating with them on this important work,” said Michel Pairet, member of Boehringer Ingelheim’s Board of Managing Directors.

Boehringer Ingelheim expects to close the transaction in the first quarter of 2021.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Zifo RnD Solutions coming to Basel
Basel Area Business & Innovation, Innovation, Invest

Zifo RnD Solutions coming to Basel

Zifo RnD Solutions, a global provider of IT solutions for research-based organizations, opens its latest subsidiary in Basel. With Zifo...

Read More
Announcing the chosen ventures for the DayOne Accelerator (2020/2021)
Basel Area Business & Innovation, Innovation

Announcing the chosen ventures for the DayOne Accelerator (2020/2021)

The DayOne Accelerator ventures for 2020/21 have been chosen. Over 100 teams applied for the program which will run from...

Read More
«We will show the new product at the Olympic Games 2021 in Tokyo»
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

«We will show the new product at the Olympic Games 2021 in Tokyo»

The new Basel Area Business & Innovation Podcast offers exciting conversations with interesting interview partners. The first guest is surgeon...

Read More
Announcing the final winners of the i4Challenge 2020
Basel Area Business & Innovation, Innovation

Announcing the final winners of the i4Challenge 2020

The expert jury of the i4Challenge selected this year's winners. The solutions from the field of Industry 4.0 range from...

Read More
Patients stand to benefit from innovative tech project
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Patients stand to benefit from innovative tech project

The investment and innovation promotion agency Basel Area Business & Innovation is joining forces with several partners to realize a...

Read More
Boehringer Ingelheim acquires Basel’s NBE-Therapeutics
Basel Area Business & Innovation, Innovation, Invest

Boehringer Ingelheim acquires Basel’s NBE-Therapeutics

German pharma group Boehringer Ingelheim is to acquire the Basel life sciences company NBE-Therapeutics for €1.18 billion. NBE-Therapeutics specializes in...

Read More
1 2 3 38

Do you have a question? We'd like to hear from you.